Ellis Investment Partners’s VanEck Biotech ETF BBH Stock Holding History

Ellis Investment Partners’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-111	Closed	-$15K	–	248
2022 Q3	$15K	Sell	111 -240	-68%	-$36.3K	﹤0.01%	516
2022 Q2	$51K	Hold	351	–	–	0.01%	403
2022 Q1	$56K	Hold	351	–	–	0.01%	403
2021 Q4	$66K	Hold	351	–	–	0.02%	383
2021 Q3	$70K	Hold	351	–	–	0.02%	358
2021 Q2	$70K	Hold	351	–	–	0.02%	356
2021 Q1	$62K	Hold	351	–	–	0.02%	356
2020 Q4	$60K	Sell	351 -8	-2%	-$1.32K	0.02%	351
2020 Q3	$58K	Hold	359	–	–	0.02%	344
2020 Q2	$59K	Hold	359	–	–	0.02%	329
2020 Q1	$44K	Hold	359	–	–	0.02%	319
2019 Q4	$50K	Hold	359	–	–	0.02%	339
2019 Q3	$41K	Hold	359	–	–	0.01%	363
2019 Q2	$46K	Buy	+359	New	+$44.3K	0.02%	336

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TIA

Traphagen Investment Advisors Oradell, New Jersey $1.4B AUM 19.32% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PGFC

Peapack-Gladstone Financial Corp Bedminster, New Jersey $7.82B AUM 21.06% 1-Year Est. Return

CIG

Consolidated Investment Group Englewood, Colorado $922M AUM 28.87% 1-Year Est. Return

Ellis Investment Partners's BBH Position: Q4 2022 in Review

Ellis Investment Partners sold out of VanEck Biotech ETF (BBH) in Q4 2022, closing a stake of 111 shares — an estimated $15K sold.

Ellis Investment Partners first reported a position in BBH in Q2 2019 and held it in 14 quarters. The position peaked at $70K in Q3 2021. 120 funds tracked by Wall St. Rank hold BBH as of Q4 2022.

Ellis Investment Partners reported no remaining VanEck Biotech ETF position as of Q4 2022 after selling out during the quarter.
Ellis Investment Partners sold 111 VanEck Biotech ETF shares in Q4 2022, an estimated $15K.
Ellis Investment Partners first reported a position in VanEck Biotech ETF in Q2 2019 and held it in 14 quarters.
Ellis Investment Partners's VanEck Biotech ETF position peaked at $70K in Q3 2021.
120 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q4 2022.

Based on Ellis Investment Partners's 13F filing for Q4 2022, filed 31 Jan 2023.